Funding: Approximately $4.5M to fund one award, with a total cost cap of $4.5M per award for a maximum performance period of 4 years.
Doc Type: BAA
Clearance:No
Program Manager: help@eBRAP.org
Last Updated: 2026-08-19 14:48
Analyzed File:HT942526TERPCTA_GG.pdf
Eligibility Reasoning
Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities. ... applications involving multidisciplinary collaborations among academia, industry, the DOW, the VA and other federal government agencies are highly encouraged.
Note: This is an AI-generated summary...
Summary
This is a Grant or Cooperative Agreement from the Defense Health Agency's (DHA) Fiscal Year 2026 (FY26) Toxic Exposures Research Program (TERP) for a Clinical Trial Award (CTA). The award (HT942526TERPCTA) supports the advancement and execution of clinical trials—ranging from small proof-of-concept to large-scale efficacy studies—with the potential to significantly impact the prevention, treatment, or management of health conditions associated with military-related toxic exposures. The program anticipates funding one award with a total cost cap of $4.5 million over a maximum performance period of four years. A key feature is the Partnering Principal Investigator Option (PPIO) to encourage interdisciplinary collaboration. Applicants must propose a clinical trial (preclinical research is not supported), provide preliminary data, and address at least one of the TERP program goals (Predict and Prevent, Diagnose, Treat) and one of its topic areas (Neurotoxin Exposure; Gulf War Illness and Its Treatment; Airborne Hazards and Burn Pits; or Other Military Service-Related Toxic Exposures). Pre-applications are due by August 19, 2026, with full applications due by November 19, 2026, upon invitation.
Overall Technical Areas
Clinical Trial DesignToxic Exposure Health EffectsPharmacologic InterventionsMedical Device EvaluationBiomarker IdentificationDiagnostic Assay DevelopmentEnvironmental Exposure MonitoringReproductive Health ToxicologyNeurotoxin Exposure ResearchGulf War Illness (GWI) ResearchAirborne Hazards ResearchStatistical Analysis & ModelingHuman Biospecimen AnalysisMechanistic ToxicologyCommon Data Element (CDE) Integration
Probable LBNL Areas
N/A
Focus Areas
Example Priorities:
Identify strategies that can anticipate, identify, monitor, and prevent adverse effects of exposures to toxic substances.
Understand the mechanisms of multigenerational effects of military-related toxic exposures and the impact of these exposures on reproductive health to aid in predicting/preventing the effects.
Identify biological and/or psychosocial variables and risk factors that can impact disease outcomes from toxic exposures.
Develop, adapt, validate, or optimize monitoring, for example, personal devices to detect and characterize individual environmental exposures.
Understand the clinical signs, symptoms, and outcomes associated with exposures; and predict disease progression to develop specific or improved diagnostics.
Understand complex, multi-exposure/physiological or nonchemical stressor (e.g., hormonal, sleep disorders, thermal stress) combinations, and how exposure impacts outcome.
Identify biomarkers of exposure to individual or multiple toxic substances alone or in combination with physiological/nonchemical stressors.
Develop diagnostic screens/assays/devices for toxic exposures.
Minimize symptoms and disease progression associated with exposures.
Develop new or improve existing therapeutics, treatments and strategies.
Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), medical devices, clinical guidance, and/or emerging approaches and technologies.
Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.
Specific Technical Skills:
Clinical Trial DesignPharmacologyTherapeutic DevelopmentMedical Device EngineeringRegulatory AffairsPatient Care ManagementHealth Outcomes ResearchGCP GuidelinesBiostatisticsDrug Development
Potential PIs for this Area:
Name
Score
Organization
Potential LBNL PIs (Overall)
Note on PI Matching: These suggestions are generated through an AI-driven semantic analysis of LBNL staff profiles.
BSA | Env. Genomics & Sys. Biology | BioSystems Data Science · Common Data Element (CDE) Integration
Fundamental Research Exemption (FRE)
In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities.
ONHS Funding Opportunity Report